Cargando…
Disease trajectory of SLE clinical endpoints and covariates affecting disease severity and probability of response: Analysis of pooled patient‐level placebo (Standard‐of‐Care) data to enable model‐informed drug development
Systemic lupus erythematosus (SLE) is an autoimmune disease affecting multiple organ systems. Many investigational agents have failed or shown only modest effects when added to standard of care (SoC) therapy in placebo‐controlled trials, and only two therapies have been approved for SLE in the last...
Autores principales: | Goteti, Kosalaram, French, Jonathan, Garcia, Ramon, Li, Ying, Casset‐Semanaz, Florence, Aydemir, Aida, Townsend, Robert, Mateo, Cristina Vazquez, Studham, Matthew, Guenther, Oliver, Kao, Amy, Gastonguay, Marc, Girard, Pascal, Benincosa, Lisa, Venkatakrishnan, Karthik |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9931431/ https://www.ncbi.nlm.nih.gov/pubmed/36350330 http://dx.doi.org/10.1002/psp4.12888 |
Ejemplares similares
-
Designing phase I oncology dose escalation using dose–exposure–toxicity models as a complementary approach to model‐based dose–toxicity models
por: Pantoja, Kristyn, et al.
Publicado: (2022) -
Comparison of Various Phase I Combination Therapy Designs in Oncology for Evaluation of Early Tumor Shrinkage Using Simulations
por: Seurat, Jérémy, et al.
Publicado: (2020) -
Diversity and Inclusion in Drug Development: Rethinking Intrinsic and Extrinsic Factors with Patient Centricity
por: Venkatakrishnan, Karthik, et al.
Publicado: (2021) -
The incidence of arthropathy adverse events in efalizumab-treated patients is low and similar to placebo and does not increase with long-term treatment: pooled analysis of data from Phase III clinical trials of efalizumab
por: Pincelli, Carlo, et al.
Publicado: (2006) -
Exposure–response analyses for the MET inhibitor tepotinib including patients in the pivotal VISION trial: support for dosage recommendations
por: Xiong, Wenyuan, et al.
Publicado: (2022)